Boston Scientific · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← BSX

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q2	2026-06-30	5.44	+7.5%	70.7%	1.18	—	—	1.28	0.61	—	—
FY2026 Q1	2026-03-31	5.20	+11.6%	69.4%	1.10	—	—	0.17	0.90	—	—
FY2025 Q4	2025-12-31	5.29	+15.8%	69.6%	0.83	—	—	1.01	0.45	—	—
FY2025 Q3	2025-09-30	5.07	+20.3%	69.9%	1.05	—	—	1.16	0.51	—	—
FY2025 Q2	2025-06-30	5.06	+22.8%	67.7%	0.82	—	—	1.13	0.53	—	—
FY2025 Q1	2025-03-31	4.66	+20.9%	68.8%	0.92	—	—	0.35	0.45	—	—
FY2024 Q4	2024-12-31	4.56	+22.5%	67.9%	0.68	—	—	1.18	0.38	—	0.00
FY2024 Q3	2024-09-30	4.21	+19.3%	68.8%	0.73	—	—	0.82	0.32	—	0.00
FY2024 Q2	2024-06-30	4.12	+14.5%	69.2%	0.52	—	—	0.66	0.22	—	0.00
FY2024 Q1	2024-03-31	3.86	+13.8%	68.6%	0.68	—	—	-0.02	0.33	—	0.00
FY2023 Q4	2023-12-31	3.73	+14.9%	69.2%	0.58	—	—	0.69	0.34	—	0.00
FY2023 Q3	2023-09-30	3.53	+11.3%	68.8%	0.69	—	—	0.51	0.34	—	0.00
FY2023 Q2	2023-06-30	3.60	—	70.6%	0.51	—	—	0.52	0.18	—	0.01
FY2023 Q1	2023-03-31	3.39	—	69.3%	0.55	—	—	0.08	0.21	—	0.01
FY2022 Q4	2022-12-31	3.24	—	68.8%	0.40	—	—	0.60	0.09	—	0.01
FY2022 Q3	2022-09-30	3.17	—	69.1%	0.36	—	—	0.32	0.12	—	0.01

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.